TAM Receptor
Tyro3; Axl; Mer
TAM receptors, comprising of Tyro3, Axl and Mertk receptors, are receptor tyrosine kinases (RTKs) that are expressed by multiple immune cells including NK cells. The TAM family of receptors and their ligands Gas6 and Protein S (PROS1) are required for the optimal phagocytosis of apoptotic cells in the mature immune, nervous, and reproductive systems.
TAMs are three homologous type I receptor-tyrosine kinases that are activated by endogenous ligands, PROS1 and GAS6. These ligands can either activate TAMs as soluble factors, or, in turn, opsonize phosphatidylserine (PS) on apoptotic cells (ACs) and serve as bridging molecules between ACs and TAMs. Abnormal expression and activation of TAMs have been implicated in promoting proliferation and survival of cancer cells, as well as in suppressing anti-tumor immunity.
TAM Receptor Isoform Specific Products
All Product Categories
-
TAM Receptor Related Products (108)
Related Products (108)
-
Recombinant Proteins (34)
-
Antibodies (2)
-
TAM Receptor Isoform Comparison
-
UNC3133
0 ImagesCat. No.: HY-115778CAS No.: 2011034-35-6
-
Axl-IN-12
0 ImagesCat. No.: HY-147579CAS No.: 2758062-17-6Axl-IN-12 (Example 2) is a potent AXL inhibitor. Axl-IN-12 can be used for the research of proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancers, viral infectious diseases or other diseases of mammals.
-
AXL-IN-15
0 ImagesCat. No.: HY-153441CAS No.: 1954722-22-5
-
Axl-IN-7
0 ImagesCat. No.: HY-147574CAS No.: 1770821-83-4Axl-IN-7 (Chemie 22) is a potent AXL inhibitor. Axl-IN-7 can be used for Axl-related diseases research, for example cancers (such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glial tumors), renal disease, immune system disorders, and cardiovascular disease.
-
NTQ2494
0 ImagesCat. No.: HY-183774CAS No.: 2750027-59-7
-
Axl-IN-19
0 ImagesCat. No.: HY-176204CAS No.: 2870696-46-9
-
MerTK-IN-1
0 ImagesCat. No.: HY-169208CAS No.: 3036376-10-7MerTK-IN-1 (compund 31) is a MerTK inhibitor with in vivo target binding ability.
-
Axl-IN-8
0 ImagesCat. No.: HY-147575CAS No.: 2231424-62-5Axl-IN-8 (NO.1) is a potent AXL inhibitor, with an IC50 of <1 nM. Axl-IN-8 also inhibits c-MET, with an IC50 of 1-10 nM. Axl-IN-8 shows anti-proliferative activity against BaF3/TEL-AXL, MKN45, and EBC-1 cells, with IC50 values of <10, 226.6 and 120.3 nM, respectively.
-
Anticancer agent 109
0 ImagesCat. No.: HY-149092CAS No.: 2097497-16-8Anticancer agent 109 (compound 6-15) is an inhibitor of the Gas6-Axl axis with anti-cancer activity. Anticancer agent 109 inhibits the expression of Gas6 and Axl, and the expression p-PI3K and p-AKT in cancer cells, leads to G1 phase arrest and promotes cancer cells apoptosis, and inhibits tumor growth significantly in nude mouse tumor bearing models.
-
Bemcentinib-d8
0 ImagesCat. No.: HY-15150SSynonyms: R428-d8; BGB324-d8Bemcentinib-d8 (R428-d8) is the deuterium labeled Bemcentinib (HY-15150). Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC50 of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer.
-
MerTK-IN-2
0 ImagesCat. No.: HY-174160MerTK-IN-2 (compound 15f) is an orally active MerTK inhibitor with an IC50 of 37.5 nM. MerTK-IN-2 can induce apoptosis. MerTK-IN-2 has antitumor activity with IC50 values of 1.79, 18.32, and 2.18 μM for human ovarian cancer cells A2780, breast cancer cells MDA-MB-231, and colon cancer cells HCT116, respectively.
-
Axl-IN-3
0 ImagesCat. No.: HY-144706CAS No.: 2783991-34-2
-
UNC8969
0 ImagesCat. No.: HY-162406CAS No.: 3036049-17-6UNC8969 (compound 43) is a MERTK/AXL dual inhibitor with IC50s of 1.1±0.8 nM for MERTK and 5.3 ± 2.7 nM for AXL. UNC8969 also exerts a T1/2 of 7.3 h with 5 mg/kg i.v. in mice.
-
R916562
0 ImagesCat. No.: HY-104075CAS No.: 1037798-41-6R916562 is an orally active and selective Axl/VEGF-R2 inhibitor with IC50s of 136 nM and 24 nM, respectively. R916562 has anti-angiogenesis and anti-metastasis.
-
AXL-IN-14
0 ImagesCat. No.: HY-152075CAS No.: 2947506-65-0AXL-IN-14 is a potent and orally active AXL inhibitor with an IC50 value of 0.8 nM. AXL-IN-14 inhibits Gas6/AXL-mediated cell migration and invasion. AXL-IN-14 decreases the expression of p-AXL and p-AKT proteins. AXL-IN-14 shows anti-tumor activity.
-
Axl-IN-5
0 ImagesCat. No.: HY-146596CAS No.: 2642224-24-4Axl-IN-5 (compound 1) is a AXL inhibitor with an IC50 of 283 nM. Axl-IN-5 has anticancer effects.
-
(Z)-S49076 hydrochloride
0 ImagesCat. No.: HY-12965BCAS No.: 1265965-19-2(Z)-S49076 hydrochloride is an orally active inhibitor of MET and AXL that blocks the downstream signaling of these receptors both in vitro and in vivo, inhibiting the proliferation and migration of tumor cells and suppressing tumor growth in xenograft models. (Z)-S49076 hydrochloride is capable of overcoming the resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) due to MET amplification in Erlotinib (HY-50896)-resistant cell lines both in vitro and in vivo. (Z)-S49076 hydrochloride can be used for research in non-small cell lung cancer (NSCLC).
-
Protein kinase inhibitor 10
0 ImagesCat. No.: HY-169517CAS No.: 871317-00-9Protein kinase inhibitor 10 is a protein kinase inhibitor with IC50 values of 28.9, 13.6, and 2.41 μM for TAM receptor, FAK, and KIT, respectively. Protein kinase inhibitor 10 can inhibit abnormal and excessive cell proliferation, showing promise for research in cancer therapy.
